A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
Status:
Not yet recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that
will be used in the Phase 3b part of this clinical trial. The goal of the Phase 3b part is to
assess the efficacy of SNP-ACTH (1-39) Gel relative to rituximab in patients with primary
membranous nephropathy (PMN) at month 24.